These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 12601130)

  • 1. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB
    Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabis and cannabinoids.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):97-8. PubMed ID: 27466748
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
    Oreja-Guevara C
    Rev Neurol; 2012 Oct; 55(7):421-30. PubMed ID: 23011861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J; Hoogervorst EL; Reif M; Kalkers NF; Van Loenen AC; Staats PG; Gorter RW; Uitdehaag BM; Polman CH
    Neurology; 2002 May; 58(9):1404-7. PubMed ID: 12011290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Metz L; Page S
    Lancet; 2003 Nov; 362(9395):1513. PubMed ID: 14615102
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM; DasGupta R; Dalton C; Wiseman OJ; Berkley KJ; Fowler CJ
    Mult Scler; 2004 Aug; 10(4):425-33. PubMed ID: 15327041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT; Makela P; Robson P; House H; Bateman C
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review.
    Martinez-Paz C; García-Cabrera E; Vilches-Arenas Á
    Cannabis Cannabinoid Res; 2023 Aug; 8(4):580-588. PubMed ID: 37057959
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
    J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.